Mice with Cisplatin and Oxaliplatin-Induced Painful Neuropathy Develop Distinct Early Responses to Thermal Stimuli

Ta, Lauren E.; Low, P. A.; Windebank, Anthony J.

doi:10.1186/1744-8069-5-9

Cited by 128 publications

(157 citation statements)

References 62 publications

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…51 After this, Aloe et al 52 also reported a heat hypoalgesia with a decrease in catecholaminergic nerve fibers density and an increase in substance P levels. More recently, Ta et al 45 have developed a model with a reported mechanical allodynia and a heat hyperalgesia (Table 2).…”

Section: Platinum Compoundsmentioning

confidence: 99%

Animal Models of Chemotherapy-Evoked Painful Peripheral Neuropathies

et al. 2009

View full text Add to dashboard Cite

Summary:This review examines recent preclinical research on toxic peripheral neuropathy and potential therapeutic developments. Chemotherapy-induced peripheral neurotoxicity is a major clinical problem because it represents the dose-limiting side effects of a significant number of antineoplastic drugs. Patients are unable to complete full or optimal treatment schedules. The incidence of chemotherapy-induced peripheral neuropathy varies depending on the drugs and schedules used, and this can be quite high, particularly when neurophysiological methods are used to make a diagnosis. However, even when chemotherapy-induced peripheral neuropathy is not a doselimiting side effect, its onset may severely affect the quality of life of cancer patients and cause chronic discomfort. As such, improved understanding of the pathophysiology of chemotherapy-induced neurotoxicity need for animal models is clinically relevant and will assist in the development of future neuroprotective strategies and also in the design of novel chemotherapies with improved toxicity profiles. In this review, the features of animal models of chemotherapy-induced painful neuropathy developed for 20 years, due to the administration of the most widely used drugs, such as platinum drugs, taxanes, and vinca alkaloids, will be discussed. In a second part, data available on neuroprotectants and treatment strategies, evaluated using these previous animal models in the attempt to prevent neuropathic pain, will be summarized.

show abstract

Section: Platinum Compoundsmentioning

confidence: 99%

Animal Models of Chemotherapy-Evoked Painful Peripheral Neuropathies

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Cold hyperalgesia was evaluated in mice using the protocol described by Ta et al (38). Mice were treated daily with 3 mg/kg of oxaliplatin or vehicle for 5 days followed by 5 days of rest, for 2 cycles.…”

Section: In Vivo Study Of Oxaliplatin-induced Neuropathy In Micementioning

confidence: 99%

Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir

Coriat¹,

Alexandre²,

Nicco³

et al. 2013

J. Clin. Invest.

View full text Add to dashboard Cite

Background. The majority of patients receiving the platinum-based chemotherapy drug oxaliplatin develop peripheral neurotoxicity. Because this neurotoxicity involves ROS production, we investigated the efficacy of mangafodipir, a molecule that has antioxidant properties and is approved for use as an MRI contrast enhancer.Methods. The effects of mangafodipir were examined in mice following treatment with oxaliplatin. Neurotoxicity, axon myelination, and advanced oxidized protein products (AOPPs) were monitored. In addition, we enrolled 23 cancer patients with grade ≥2 oxaliplatin-induced neuropathy in a phase II study, with 22 patients receiving i.v. mangafodipir following oxaliplatin. Neuropathic effects were monitored for up to 8 cycles of oxaliplatin and mangafodipir. Funding.

show abstract

“…It is a determinant of muscular strength and an indicator of neuromuscular function. Method used has been described previously by Ta et al [18]. The grip strength meter was positioned horizontally and rats held by the tail were allowed to grasp the smooth, metal pull bar (forelimbs only).…”

Section: Forelimb Grip Strengthmentioning

confidence: 99%

Effect of L-carnitine Supplementation on Nutritional Status and Physical Performance Under Calorie Restriction

Jain

Singh

2014

Ind J Clin Biochem

View full text Add to dashboard Cite

L-carnitine is popular as a potential ergogenic aid because of its role in the conversion of fat into energy. The present study was undertaken to investigate the effect of short term supplementation of L-carnitine on metabolic markers and physical efficiency tests under short term calorie restriction. Male albino rats were divided into four groups (n = 12 in each)-control, calorie restricted (CR for 5 days, 25 % of basal food intake), L-carnitine supplemented (CAR, given orally for 5 days at a dose of 100 mg/kg), CR with L-carnitine supplementation (CR ? CAR). Food intake and body weight of the rats were measured along with biochemical variables like blood glucose, tissue glycogen, plasma and muscle protein and enzymatic activities of CPT-1 (carnitine palmitoyl transferase-1) and AMP kinase. Results demonstrated that Lcarnitine caused marked increase in muscle glycogen, plasma protein, CPT-1 activity and swim time of rats (P \ 0.05) on short term supplementation. In addition to the substantive effects caused by CR alone, L-carnitine under CR significantly affected muscle glycogen, plasma protein, CPT-1 activity and AMP kinase (P \ 0.05). Short term CR along with L-carnitine also resulted in increased swim time of rats than control, CR and L-carnitine treated rats (P \ 0.05). The present study was an attempt towards developing an approach for better adherence to dietary restriction regimen, with the use of L-carnitine.

show abstract

Mice with Cisplatin and Oxaliplatin-Induced Painful Neuropathy Develop Distinct Early Responses to Thermal Stimuli

Cited by 128 publications

References 62 publications

Animal Models of Chemotherapy-Evoked Painful Peripheral Neuropathies

Animal Models of Chemotherapy-Evoked Painful Peripheral Neuropathies

Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir

Effect of L-carnitine Supplementation on Nutritional Status and Physical Performance Under Calorie Restriction

Contact Info

Product

Resources

About